Systems for treating pulmonary infections

摘要

Provided herein are systems for treating a subject with a pulmonary infection, for example, a nontuberculous mycobacterial pulmonary infection, a Burkholderia pulmonary infection, a pulmonary infection associated with bronchiectasis, or a Pseudomonas pulmonary infection. The system includes a pharmaceutical formulation comprising a liposomal aminoglycoside dispersion, and the lipid component of the liposomes consist essentially of electrically neutral lipids. The system also includes a nebulizer which generates an aerosol of the pharmaceutical formulation at a rate greater than about 0.53 gram per minute. The aerosol is delivered to the subject via inhalation for the treatment of the pulmonary infection.

主权项

1. A system for treating or providing prophylaxis against a pulmonary infection in a patient, comprising:
(a) a pharmaceutical formulation comprising an aqueous dispersion of liposomal complexed aminoglycoside, wherein the lipid component of the liposomal complexed aminoglycoside is present at 45-60 mg/mL and consists of dipalmitoylphosphatidylcholine (DPPC) and cholesterol, and (b) a nebulizer comprising a vibrating mesh membrane, which generates an aerosol of the pharmaceutical formulation at a rate of 0.60 g per minute to 0.80 g per minute, wherein the fine particle fraction (FPF) of the aerosol is greater than or equal to about 64%, as measured by the Andersen Cascade Impactor (ACI), or greater than or equal to about 51%, as measured by the Next Generation Impactor (NGI) and the percent associated aminoglycoside of the aerosol is from 60% to 70%.